Lipoprotein-Associated Phospholipase A2: Relation to Development of Ischemic Stroke in Patients With Essential Hypertension

Полупанов, А. Г.; Lomteva, J.N. Lomteva; Халматов, А. Н.; Cheskidova, Natalia; Romanova, Tatyana; Джумагулова, А. С.

doi:10.18565/cardio.2014.6.29-34

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 36 ] The findings of the current study pointed out that patient with ischemic stroke showed elevated levels of Lp-PLA2 mass compared to the controls as corresponding with Polupanov et al ., a study that demonstrated a significant association between high Lp-PLA2 mass levels and ischemic stroke. [ 37 ] Likewise, there is a higher expression of Lp-PLA2 and its products in carotid plaque in patients with ischemic stroke. Therefore, higher Lp-PLA2 mass levels were linked with the development and progression of atherosclerotic changes which are responsible for atherogenesis and ischemic stroke.…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Al-Kuraishy

Al-Gareeb

Waheed

2018

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

Objectives:The objective of the study is to investigate the effects of statins on the lipoprotein-associated phospholipase A2 (Lp-PLA2) mass in patients with ischemic stroke.Materials and Methods:A total number of 59 patient ages 43–69 years with cerebral stroke compared to 39 healthy controls that matching the age and body weight. The patients were divided into 32 patients on statins therapy assigned as statins users and 27 patients, not on statins therapy assigned as nonstatins users. Anthropometric and biochemical measurements were done including lipid profile and inflammatory biomarkers.Results:Stroke patients on statins therapy showed a comparable low of Lp-PLA (29.82 ± 3.19 IU/mL) to nonstatins user stroke patients (15.58 ± 5.73 IU/mL). Lp-PLA2 mass levels were positively correlated with body mass index, blood pressure changes, total cholesterol, triglyceride, and very low-density lipoprotein and stroke risk (SR) percentage.Conclusions:Patients on statins with ischemic stroke had low levels of Lp-PLA2 mass levels compared to nonstatins user with ischemic stroke. Lp-PLA2 mass levels were higher in men than women and correlated with lipid profile and SR in patients with ischemic stroke.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Al-Kuraishy

Al-Gareeb

Waheed

2018

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

show abstract

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Vijayan

Reddy

2016

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

103

View full text Add to dashboard Cite

Stroke is the second leading cause of death in the world. Stroke occurs when blood flow stops, and that stoppage results in reduced oxygen supply to neurons in the brain. The occurrence of stroke increases with age, but anyone at any age can suffer from stroke. Recent research has implicated multiple cellular changes in stroke patients, including oxidative stress and mitochondrial dysfunction, inflammatory responses, and changes in mRNA and proteins. Recent research has also revealed that stroke is associated with modifiable and non-modifiable risk factors. Stroke can be controlled by modifiable risk factors, including diet, cardiovascular, hypertension, smoking, diabetes, obesity, metabolic syndrome, depression and traumatic brain injury. Stroke is the major risk factor for vascular dementia (VaD) and Alzheimer’s disease (AD). The purpose of this article is to review the latest developments in research efforts directed at identifying 1) latest developments in identifying biomarkers in peripheral and central nervous system tissues, 2) changes in microRNAs (miRNAs) in patients with stroke, 3) miRNA profile and function in animal brain, and 4) protein biomarkers in ischemic stroke. This article also reviews research investigating circulatory miRNAs as peripheral biomarkers of stroke.

show abstract

Mallignant ischemic stroke: clinical and biochemical features of diagnosis

Gluschenkova,

Sarkisian,

Goncharova

2023

jour

View full text Add to dashboard Cite

Ischemic stroke (IS) remains the most common neurological pathology [1,2] and can manifest itself in the form of malignant ischemic stroke (MIS), leading not only to severe disability of the patient, but to life-threatening conditions [3,4]. Malignant ischemic stroke is one of the most formidable manifestations of ischemic stroke, threatening disability of the working population and the likelihood of death without the appointment of timely therapy. Diagnosis:“Malignant ischemic stroke” can occur no earlier than 12-24 hours, during which time irreversible changes in the brain may occur, accompanied by its pronounced edema, with the threat of subsequent herniation, therefore, the appointment of adequate and timely therapy is necessary as soon as possible [5,6] . Taking into account the peculiarities of the course of the disease, there is a need to search for predictors of MIS. In order to timely predict irreversible consequences, in the above literature review, we consider modern approaches to diagnosing the malignant course of ischemic stroke. The analysis of the literature data allows us to determine some clinical and laboratory predictors of the development of malignant ischemic stroke and methods for assessing the severity of ischemic stroke. Various possibilities of using the studied markers for the purpose of practical use in the early diagnosis of MIS are considered. Based on the literature data, the possibilities of diagnostics were analyzed in order to prescribe timely and adequate therapy before the onset of irreversible changes in the brain.

show abstract

Lipoprotein-Associated Phospholipase A2: Relation to Development of Ischemic Stroke in Patients With Essential Hypertension

Cited by 4 publications

References 0 publications

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Mallignant ischemic stroke: clinical and biochemical features of diagnosis

Contact Info

Product

Resources

About